All of our eight candidate genes showed statistically significantly different expression between normal/benign prostate and malignant PCa sample groups, low versus high Gleason grade tumors (PLA2G7), PSA relapse versus no relapse (SPON2), and low versus high TNM stages (CACNA1D and DLX1). The gene discussed is PLA2G7; the disease is cancer.